The diagnostic specialty antibodies market has seen considerable growth due to a variety of factors.
•In recent years, there has been a substantial expansion in the diagnostic specialty antibodies market size. It is anticipated to escalate from $29.62 billion in 2024 to about $31.26 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%.
The growth experienced in the prior period can be credited to breakthroughs in biotechnology, the development of personalized medicine, enhanced understanding of diseases, immunoassay and diagnostic approaches, along with the ascent of companion diagnostics.
The diagnostic specialty antibodies market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of diagnostic specialty antibodies is anticipated to witness substantial expansion in the years to come, reaching a valuation of $40.49 billion by 2029 with a compound annual growth rate (CAGR) of 6.7%.
Drivers of this growth in the forecasted period include the proliferation of disease biomarkers, the acceleration of point-of-care testing, the emergence of infectious diseases, development of biosimilars and generics, as well as the incorporation of artificial intelligence and machine learning. The forecast period is also likely to see key trends such as advancements in assay technology, the application of nanotechnology, improved specificity and selectivity, integration with wearable tech gadgets, and ongoing assay miniaturization.
The diagnostic specialty antibodies market is poised for significant growth, driven by a larger pool of individuals being diagnosed with HIV. As more people are diagnosed with HIV, we witness an expansion in this market, providing scope for manufacturers to design and distribute unique antibody-based diagnostic tools for HIV testing. Such products aid in identifying specific HIV biomarkers, permitting early detection and monitoring of the HIV infection. For instance, the UK Health Security Agency's report revealed that the HIV testing rate surged by 11% between 2022 and 2023. It was most prevalent among gay, bisexual, and other men engaging in sex with men (GBMSM), at a rate of 52,255 per 100,000 in 2023. On the other hand, the rates were notably lower for heterosexual men and heterosexual and bisexual women - at 1,894 and 3,106 per 100,000, respectively. Hence, the enlarging pool of HIV diagnosed individuals is fuelling the growth of the diagnostic specialty antibodies market.
The diagnostic specialty antibodies market covered in this report is segmented –
1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies
2) By Application: Hepatitis, Tuberculosis, Dengue, Oncology, Human Immunodeficiency Virus (HIV), Infectious Disease, Other Applications
3) By End User: Diagnostic Laboratories, Hospitals
Subsegments:
1) By Monoclonal Antibodies: Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Polyclonal Antibodies: Rabbit Polyclonal Antibodies, Goat Polyclonal Antibodies, Sheep Polyclonal Antibodies
3) By Recombinant Polyclonal Antibodies: Single-Chain Variable Fragment (scFv), Fab Fragments
Innovations in product offerings is a primary emerging trend within the market for diagnostic specialty antibodies. Major market players are aiming to consolidate their market standing by unveiling unique products and solutions. To illustrate, Creative Diagnostics, a US firm that supplies raw materials, antibodies, and reagents for the biotech industry, launched a range of 1,000 new items in January 2023. Their release incorporated carrier-free formulations and conjugated antibodies, thus reinforcing their portfolio of monoclonal antibodies and extending their services to global customers. These newly debuted monoclonal antibodies are versatile and high-performing, with applications as ELISA (enzyme-linked immunoassay) detection tools in direct, indirect, and sandwich ELISA approaches, and offer enhanced specificity due to their capability for single-epitope recognition. Furthermore, these antibodies, having passed through stringent validation, are applicable for an array of uses, including Western blotting (WB), flow cytometry (FC), immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), along with immunoprecipitation (IP).
Major companies operating in the diagnostic specialty antibodies market include:
• F. Hoffmann-La Roche AG
• Sanofi SA
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Boehringer Ingelheim International GmbH
• Merck KGaA
• Becton Dickinson and Company
• Regeneron Pharmaceuticals Inc
• Agilent Technologies Inc.
• Sartorius AG
• Bio-Rad Laboratories Inc.
• Quest Diagnostics Inc.
• STEMCELL Technologies Inc.
• Abcam PLC
• Telix Pharmaceuticals Limited
• Aytu BioScience Inc.
• Enzo Life Sciences Inc.
• Rockland Immunochemicals Inc.
• Santa Cruz Biotechnology Inc.
• Creative Diagnostics
• Novus Biologicals LLC
• Precirix NV
• Creative Biolabs Inc.
• Polymun Scientific ImmunbiologischeForschung GmbH.
North America was the largest region in the diagnostic specialty antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diagnostic specialty antibodies market report during the forecast period. The regions covered in the diagnostic specialty antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.